Browse

Desmopressin is an Effective Treatment for Mixed Nocturia with Nocturnal Polyuria and Decreased Nocturnal Bladder Capacity

DC Field Value Language
dc.contributor.authorLee, Hye Won-
dc.contributor.authorChoo, Myung-Soo-
dc.contributor.authorLee, Jeong Gu-
dc.contributor.authorPark, Choal Hee-
dc.contributor.authorLee, Jeong Zoo-
dc.contributor.authorPark, Won Hee-
dc.contributor.authorLee, Kyu-Sung-
dc.contributor.authorHan, Deok Hyun-
dc.contributor.authorPaick, Jae-Seung-
dc.date.accessioned2012-06-14T06:04:43Z-
dc.date.available2012-06-14T06:04:43Z-
dc.date.issued2010-12-
dc.identifier.citationJOURNAL OF KOREAN MEDICAL SCIENCE; Vol.25 12; 1792-1797ko_KR
dc.identifier.issn1011-8934-
dc.identifier.urihttps://hdl.handle.net/10371/77068-
dc.description.abstractTo investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged >= 18 yr with mixed nocturia (>= 2 voids/night and a nocturnal polyuria index [NPi] >33% and a nocturnal bladder capacity index [NBCi] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50% or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50% or greater reduction in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4 +/- 44.1 to 220.3 +/- 90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN ACAD MEDICAL SCIENCESko_KR
dc.subjectUrinary Bladderko_KR
dc.subjectDeamino Arginine Vasopressinko_KR
dc.subjectNocturnal Polyuriako_KR
dc.subjectNocturiako_KR
dc.subjectHyponatremiako_KR
dc.titleDesmopressin is an Effective Treatment for Mixed Nocturia with Nocturnal Polyuria and Decreased Nocturnal Bladder Capacityko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이혜원-
dc.contributor.AlternativeAuthor주명수-
dc.contributor.AlternativeAuthor이정구-
dc.contributor.AlternativeAuthor박철희-
dc.contributor.AlternativeAuthor백재승-
dc.contributor.AlternativeAuthor이정주-
dc.contributor.AlternativeAuthor한덕현-
dc.contributor.AlternativeAuthor박원희-
dc.contributor.AlternativeAuthor이규성-
dc.identifier.doi10.3346/jkms.2010.25.12.1792-
dc.citation.journaltitleJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.description.citedreferenceChoo MS, 2008, NEUROUROL URODYNAM, V27, P60, DOI 10.1002/nau.20458-
dc.description.citedreferencevan Kerrebroevk P, 2007, EUR UROL, V52, P221, DOI 10.1016/j.eururo.2007.01.027-
dc.description.citedreferenceBae JH, 2007, J UROLOGY, V178, P200, DOI 10.1016/j.juro.2007.03.042-
dc.description.citedreferenceChen FY, 2007, INT UROGYNECOL J, V18, P431, DOI 10.1007/s00192-006-0167-x-
dc.description.citedreferenceIrwin DE, 2006, EUR UROL, V50, P1306, DOI 10.1016/j.eururo.2006.09.019-
dc.description.citedreferenceBing MH, 2006, BJU INT, V98, P599, DOI 10.1111/j.1464-410X.2006.06390.x-
dc.description.citedreferenceWeiss JP, 2006, J UROLOGY, V175, pS16, DOI 10.1016/S0022-5347(05)00312-5-
dc.description.citedreferenceMarinkovic SP, 2004, BRIT MED J, V328, P1063-
dc.description.citedreferenceIwasaki H, 2004, UROLOGY, V63, P994, DOI 10.1016/j.urology.2003.11.036-
dc.description.citedreferenceWeatherall M, 2004, NEUROUROL URODYNAM, V23, P302, DOI 10.1002/nau.20038-
dc.description.citedreferenceNAM S, 2004, KOREAN J UROL, V45, P49-
dc.description.citedreferenceRembratt A, 2003, BJU INT, V91, P642-
dc.description.citedreferenceWEISS JP, 2003, CURR UROL REP, V4, P362-
dc.description.citedreferenceMattiasson A, 2002, BJU INT, V89, P855-
dc.description.citedreferencevan Kerrebroeck PEV, 2002, BJU INT, V89, P420-
dc.description.citedreferencevan Kerrebroeck P, 2002, NEUROUROL URODYNAM, V21, P179, DOI 10.1002/nau.10053-
dc.description.citedreferenceKIM ET, 2001, KOREAN J UROL, V42, P1075-
dc.description.citedreferenceAsplund R, 1999, BJU INT, V83, P591-
dc.description.citedreferenceAsplund R, 1998, BRIT J UROL, V82, P642-
dc.description.citedreferenceRittig S, 1998, CLIN ENDOCRINOL, V48, P235-
dc.description.citedreferenceLethagen S, 1998, AM J HEMATOL, V57, P153-
dc.description.citedreferenceWeiss JP, 1998, NEUROUROL URODYNAM, V17, P467-
dc.description.citedreferenceMalmsten UGH, 1997, J UROLOGY, V158, P1733-
dc.description.citedreferenceNadal M, 1996, EUR J ENDOCRINOL, V134, P174-
dc.description.citedreferenceASPLUND R, 1992, SCAND J PRIM HEALTH, V10, P98-
dc.description.citedreferenceVILHARDT H, 1990, DRUG INVEST S5, V2, P2-
dc.description.citedreferenceBELMAKER RH, 1986, MIL MED, V151, P660-
dc.description.citedreferenceBLOK C, 1986, J UROLOGY, V136, P1123-
dc.description.citedreferenceKIRKLAND JL, 1983, BRIT MED J, V287, P1665-
dc.description.citedreferenceTHOMAS S, 1957, J PHYSIOL-LONDON, V139, P337-
dc.description.tc1-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse